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Introduction
According to the 2011 Criteria and Guidelines for Alzheimer’s 
disease developed by the National Institute of Health and the 
Alzheimer’s Association, there are three stages of Alzheimer’s 
disease. In the first stage, preclinical Alzheimer’s disease, patients 
exhibit no symptoms of memory loss or changes in behavior, 
but begin to form progressive pathological characteristics of the 
disease in the brain, cerebrospinal fluid, and blood. The second 
stage, mild cognitive impairment, or MCI, due to Alzheimer’s 
disease indicates noticeable changes in behavior and cognition 
that do not affect everyday life function and activities. The final 
stage is dementia due to Alzheimer’s disease. This is the stage 
in which a person exhibits distinct memory loss and cognitive 
decline that severely impairs everyday function (www.alz.org).
Although there are already measurable pathological changes 
in the brain, cerebrospinal fluid, and blood during the preclinical 
stage of Alzheimer’s disease, the changes are rarely detected 
or tested for due to the lack of symptoms. While preclinical 
Alzheimer’s is considered the first stage of the disease, the 2011 
criteria and guidelines for Alzheimer’s disease do not list diag-
nostic criteria that can be used in diagnosing it, causing the typ-
ical Alzheimer’s disease patient to be first diagnosed after years 
of the disease’s progression, and only after symptoms appear. 
In the past two decades, there has been a huge effort to devel-
op disease-modifying drugs to slow or stop the progression of 
Alzheimer’s disease. These treatments are predicted to be most 
effective in the preclinical and early mild cognitive impairment 
stages. However, because most patients partaking in clinical trials 
are already in advanced stages of the disease, many of these trials 
have failed. Therefore, specific, easily-identifiable and accessible 
biomarkers are crucial for diagnosing patients in the preclinical 
stage so that their fitness for disease-modifying treatments can 
be determined, and the effectiveness of such treatments can be 
accurately monitored (www.alz.org). Understanding specific bio-
markers would also lend patients more time to plan for their fu-
ture and would give them opportunity to be involved in decisions 
involving their home care and legal matters while their cognition 
is still intact (Gomez Ravetti, Moscato, 2008).
Current detection mechanisms of Alzheimer’s disease include 
brain imaging and cerebrospinal fluid testing. These methods, 
however, are expensive and invasive, and are not easily accessi-
ble to large portions of the population (O’Bryant et al., 2011). 
Additionally, these methods are inconclusive and are usually 
only performed once the disease has reached the mild cogni-
tive impairment or dementia stage and has already progressed 
significantly.
Researchers are therefore in search of conclusive biomark-
ers that can be used in routine screenings and detection of 
preclinical Alzheimer’s disease (Berg, 2008). Peripheral blood-
based biomarkers are ideal for Alzheimer’s disease screening, 
as they can be easily accessed via routine venipuncture, which 
is cost-effective, noninvasive, and available to majority of the 
population (O’Bryant et al., 2011). This paper explores several 
blood-based biomarker possibilities that can be used as routine 
screenings for preclinical or early-onset Alzheimer’s disease.
Alzheimer’s Disease Pathology
Although the exact pathological cause of Alzheimer’s disease is 
still unknown, there are two major pathological characteristics 
that researchers have pinpointed to indicate the disease and its 
progression. These characteristics are excessive beta-amyloid 
peptide plaques and phosphorylated tau protein deposition in 
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the brain. Through different mechanisms, these characteristics 
both cause neuronal death and eventual atrophy that spreads 
throughout the brain (Manzine et al., 2013).
In a normal, nonamyloidogenic pathway, amyloid precursor 
protein, or APP, an enzyme embedded in the cell membrane of 
neurons, is cleaved by alpha-secretase and releases a fragment 
called aAPP. aAPP is a large and insoluble molecule, and is be-
lieved to have a protective effect on the neural cells it occupies. 
aAPPs protect the neurons of the hippocampus against excito-
toxicity, A beta toxicity, and glucose deprivation (Furukawa et al., 
1996), and enhance learning and memory function. In patients 
with Alzheimer’s disease, there is a decrease in APP processing 
via a-secretases (Manzine et. al., 2013). Instead, APP is cleaved 
by beta-secretase, followed by gamma-secretase cleavage. Beta-
amyloid, the fragment produced by this pathway, is shorter than 
aAPP, and when beta-amyloid fragments aggregate, they become 
insoluble, forming beta-amyloid plaques. These plaques inter-
fere with inter-neuronal communication, causing information 
transfer at synapses to fail, eventually leading to neuronal death 
(Cummings et al., 1996).
The second pathological characteristic of Alzheimer’s disease 
is neurofibrillary tangles caused by abnormal tau protein deposi-
tion in the brain. In normal neurons, the tau protein attaches to 
microtubules and stabilizes the important internal structures of 
the cell by acting as a firm, scaffolding-like structure. Nutrients 
are carried throughout this structure, and the tau protein is 
essential for normal cell function and nutrient transport. In 
patients with Alzheimer’s disease, however, the tau protein is 
modified and behaves differently. Tau protein separates from the 
microtubules in neurons of patients with Alzheimer’s disease, 
causing the structure to fall apart. Strands of tau combine and 
form tangles inside the neuron, disabling the transport system 
and eventually destroying the cell (Ingelsson et al., 2004).
The accumulation of both beta amyloid plaque and 
neurofibrillary tangles leads to cell death. In patients with 
Alzheimer’s disease, the abundance of cell death causes the brain 
to shrink in size and many important functions, such as memory, 
to fail. Atrophy begins in the lateral entorhinal cortex, which to-
gether with the hippocampus plays an integral role in long-term 
memory storage. Over time, the brain atrophy spreads to other 
areas of the cerebral cortex, specifically to the parietal cortex, 
the region of the brain associated with navigation and spatial 
orientation (Liu et al., 2013), leading to severe cognitive decline.
Researchers are still unsure of the direct causes of beta-am-
yloid plaque accumulation and neurofibrillary tangle formation. 
They have, however, pinpointed these characteristics as the 
cause of cerebral atrophy and cognitive decline in patients with 
Alzheimer’s disease. It is therefore useful to utilize these known 
pathological markers of Alzheimer’s disease as the basis for bio-
marker research, as they are present not only in the mild cogni-
tive impairment and severe Alzheimer’s disease stages, but begin 
to form in the preclinical stage, prior to the onset of cognitive 
symptoms (www.alz.org). 
Methods
Research was done by studying original research articles and 
scientific papers found on the Touro College online library. 
Specific scientific databases such as Proquest and EBSCO were 
perused, and additional information was obtained by analyzing 
articles found.
Discussion: 
Current Detection of Alzheimer’s Disease 
Progression
Today, when there is concern for possible Alzheimer’s disease, 
there is no definitive step to reach a diagnosis. Instead, a series 
of steps must be taken to ultimately lead to a probable diagnosis 
of the disease. Even then, it is only when neurofibrillary tangles 
Figure 1: MRI scans of the brains of (i) cognitively normal (CN) patient, (ii) patient with amnesic mild cognitive impairment, and (iii) patient 
with  Alzheimer’s disease (Vemuri, Jack, 2010).
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(NFTs) in neurons, amyloid plaques, and synapse or neuronal 
loss and atrophy are found upon postmortem examination of 
the brain that Alzheimer’s disease can be fully confirmed (Berti 
et al., 2010). 
To reach a probable diagnosis of Alzheimer’s Disease, a mini 
mental state exam, or MMSE, is first performed, in which the 
patient is asked to fulfill certain tasks and answer a variety of 
questions ranging from recalling the date and time to repeat-
ing words or sentences and copying drawings and shapes. A 
gross score is assigned, and a score ranking of “cognitively im-
paired” will cause a doctor to send a patient for further testing 
(O’Bryant et al., 2008). 
Blood tests will be done to rule out other causes of demen-
tia, such as abnormal thyroid function or vitamin B-12 levels 
(Agarwal et al., 2008). The patient may then be referred to a 
neurologist or sent for brain imaging to detect more specific 
Alzheimer’s disease pathological markers or other causes of 
cognitive impairment by looking for blood accumulation, brain 
tumors, strokes, and change in brain size. 
While brain imaging such as magnetic resonance imaging 
(MRI) and positron emission topography (PET) scans are cur-
rently used on patients in the mild cognitive impairment or 
late Alzheimer’s dementia stage, there is still much uncertainty 
regarding the use of such imaging techniques in detecting the 
disease in its preclinical stage. As seen in figure 1, MRI imaging 
shows clear cerebral atrophy in patients with mild cognitive im-
pairment and Alzheimer’s disease when compared to patients 
with normal cognition (Vemuri, Jack, 2010). Several studies have 
shown that MRI detection of atrophy of the medial temporal 
lobes (MTL), the brain region responsible for language and long-
term memory, can be an indication of early AD and predicts 
conversion to dementia (Rusinek et. al., 2003). Additionally, 
Fluoro-2-deoxy-D-glucose (FDG) PET scanning has played the 
leading neuroimaging role in the early detection of Alzheimer’s 
disease by using estimates of cerebral metabolic rate of glu-
cose (CMRglc), an indication of synaptic density and function. 
Patients with Alzheimer’s disease will exhibit CMRglc reduc-
tions that are visible on FDG-PET scans, which can even be 
detected before the onset of Alzheimer’s symptoms (Berti et 
al., 2010). However, FDG-PET and MRI scans are limited as they 
lack disease specificity; other dementias exhibit reductions in 
CMRglc, as well, and there can be other causes of brain atrophy 
detected on an MRI (Wollman, Prohovnik, 2003).
Currently, cerebrospinal fluid (CSF) levels of tau protein and 
beta-amyloid plaques are the most reliable and widespread pro-
tein biomarkers used for Alzheimer’s disease detection. This is 
because cerebrospinal fluid interacts directly with extracellular 
brain space and can therefore be used as an accurate mark-
er for pathological changes in the brain (Hampel et al., 2012). 
However, obtaining cerebrospinal fluid requires a lumbar punc-
ture, or “spinal tap”, a procedure that is expensive, painful, and 
time-consuming, and usually needs to be performed in a hospi-
tal setting. Testing CSF is therefore not a practical way to screen 
for preclinical Alzheimer’s disease.
Genetic Risk Factors of Alzheimer’s Disease
Although environmental factors such as diet, exercise, and ed-
ucation play a role in the development of Alzheimer’s disease, 
twin studies strongly suggest that genetics is the major factor 
in its development (Gatz et. al., 2006). While many genes have 
been suggested as genetic risk factors, only one, the ε4 allele 
of the apolipoprotein E, or APOE, gene has been confirmed to 
directly correlate to Alzheimer’s disease development (Corder 
et. al., 1993).
APOE, a glycoprotein composed of 299 amino acids, functions 
as a ligand, combining with lipids to form lipoproteins. APOE is 
essential for cholesterol homeostasis throughout the body, and 
is the principal cholesterol carrier in the brain (Puglielli et al. 
2003). 
Every person inherits one copy of the APOE gene from each 
parent. The APOE gene has three common single nucleotide 
polymorphisms (SNPs) leading to three common isoforms of 
APOE: Apoε2, Apoε3, and Apoε4. The most common form of 
APOE is ε3, with about 60 percent of the U.S. population in-
heriting one ε3 gene from each parent.  Only about 20 to 30 
percent of the U.S. population carries one or two copies of the 
ε4 gene, and 10 to 20 percent of the population has one or two 
copies of ε2. Despite these alleles differing in only one or two 
amino acids, they have drastically different functions and cause 
stark differences in the genotype (Raber et al. 2004). 
Numerous studies have established that the Apoε3 form nei-
ther increases or decreases the risk of developing Alzheimer’s 
disease, and that the Apoε2 form may decrease the risk of 
developing the disease. The Apoε4 allele, however, is a strong 
genetic risk factor for the development of Alzheimer’s disease 
(Corder et al., 1993). Compared to people who possess no ε4 
allele, people who are heterozygous for the ε4 allele exhibit a 
2-3-fold increase in developing Alzheimer’s disease, and people 
who are homozygous for the ε4 allele exhibit a 12-fold increase 
in developing the disease (Bertram et al., 2009).
Yet despite the strong correlation between patients with 
the Apoε4 allele and the development of Alzheimer’s disease, 
the mechanism of how Apoε4 causes an increase in AB-
deposition is still not fully understood (Holtzman et al., 2012). 
Furthermore, inheriting the ε4 allele does not guarantee that 
someone will develop the disease. The ε4 allele had a signifi-
cantly weaker effect in some ethnic groups, such as African 
Americans and Hispanics (Farrer et al., 1997), suggesting that 
there are other environmental and genetic factors involved in 
the onset of Alzheimer’s disease, and that the predisposition to 
developing Alzheimer’s disease cannot be determined based on 
this gene alone. 
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Inflammatory Responses Associated with 
Alzheimer’s Disease
As with any other disease, upon sensing abnormal neuronal de-
generation caused by Alzheimer’s disease, the body launches an 
immune response (Cagnin et al., 2001).  When neurofibrillary 
tangles begin to form from abnormal tau proteins, astrocytes 
and microglia, usually inactive in brain tissue, are activated as 
part of the initial response (Leung et al., 2013).  When activated, 
microglia become phagocytes and secrete many inflammatory 
molecules such as cytokines and chemokines, growth factors, 
complement molecules and adhesion molecules. 
Several inflammatory agents have been specifically associated 
with amyloid deposits, including IL-1, IL-6, a1-antichymotrypsin 
(ACT), tumor necrosis factor-a (TNF-a), and transforming growth 
factor (TGF-b) (Mcgeer et al., 2006). When tested in blood plas-
ma, these inflammatory agents showed a positive correlation 
with beta-amyloid peptide found in cerebrospinal fluid (Sun et 
al., 2003). 
Another study was done comparing cytokine expression in 
blood plasma to neuropsychological testing and neuroimaging 
indicating Alzheimer’s disease progression. Twenty-seven cyto-
kines and chemokines (chemical messengers that cells release 
as an immune response) were tested. The study found that five 
cytokines and chemokines, IL-6, TNF-a, IL- 1ra, IL-10, and IL-13, 
were inversely related to ventricular volume, whole brain volume, 
or entorhinal cortex volume in Alzheimer’s disease. That is, the 
greater the immune response to the disease, the smaller the brain 
volume, or the further along the disease progression. There was 
also an increase in the level of two cytokines, IL-10 and IFN- γ, 
when tracked in patients between visits (Leung et. al., 2013).
Aside from acting as an immune response to the atrophy of 
brain cells, the inflammatory response itself may also be contrib-
uting to brain atrophy. According to the amyloid cascade-inflam-
matory hypothesis, researchers postulate that Alzheimer’s disease 
is caused by the inflammatory response to beta-amyloid deposits 
and is later intensified by tau protein tangles. As the disease pro-
gresses, so does the inflammatory response, and it may be for this 
reason that multiple attempts at developing disease-modifying 
drugs have failed, as they fail to take the inflammatory response 
into account. In this strain, possible therapies dealing with anti-in-
flammatory agents may show promise for developing successful 
disease-modifying drugs (McGeer et al., 2013).
In a highly-publicized study, it was hypothesized that the patho-
logical processes related to Alzheimer’s disease in the body would 
trigger an immune response with specific changes in certain signal 
proteins in the blood. A longitudinal study was done in which 
patients were tested at the initial diagnosis of Alzheimer’s disease 
with mild cognitive impairment, and were then followed up with 
two to six years later. Using an algorithm called PAM (partition 
around medoids), eighteen of the one hundred and twenty pro-
teins tested were identified as Alzheimer’s disease predictors, 
with a 95% positive agreement and 83% negative agreement with 
the clinical diagnosis (Ray et al., 2007). 
These results showed promising statistics that warranted 
additional study. The PAM algorithm was then used to predict 
Alzheimer’s disease progression in twenty-two patients with 
mild cognitive impairment. The prediction of twenty of the 
twenty-two patients to develop Alzheimer’s disease was proven 
correct when the patients were followed up with two to five 
years later (Ray et. al., 2007). This highly specific plasma bio-
marker test can therefore be used to predict Alzheimer’s dis-
ease years before a clinical diagnosis would typically be made or 
even before any symptoms appear.
A further study found that of the original nineteen predictor 
proteins found by Ray et al., just five proteins could be used with 
96% accuracy to detect preclinical Alzheimer’s disease. Using less 
proteins caused less errors in prediction, and higher biomarker 
specificity and accuracy (Gomez Ravetti, Moscato, 2008).
Immune responses to beta-amyloid deposition and neurofibril-
lary tangles, including activation of microglia and astrocytes to 
release cytokines and chemokines, can be used as an index of 
Alzheimer’s disease progression (Leung et. al., 2013).  Additionally, 
the use of specific signal proteins can be used to accurately 
predict development of Alzheimer’s disease (Ray et. al., 2007). 
Treatments aimed at dealing with these inflammatory responses 
may also prove to be effective although more research is needed 
to prove that hypothesis (McGeer, McGeer, 2013).
ADAM10 as a Biomarker
Efforts have been made to find biomarkers relating to the patho-
genic mechanism of abnormal beta-amyloid aggregation causing 
the formation of amyloid plaques. The products of the ecto-
domain shedding process, in which amyloid precursor protein 
(APP) is cleaved by a-secretase into its soluble counterparts, can 
be used as detection mechanisms of preclinical Alzheimer’s dis-
ease by methods similar to those used in measuring the immune 
response (Pruessmeyer, Ludwig, 2009).
In the amyloidogenic pathway, after APP is cleaved by β-secre-
tase, also called β-site APP-cleaving enzyme 1 (BACE1), it is then 
cleaved by a γ-secretase, leading to the release of the AB frag-
ment. BACE1 competes with the a-secretase for cleavage of the 
APP substrate, so that an increase in BACE1 activity causes a 
decrease in a-secretase activity, and vice versa (Vassar, 2013).
The identity of the a-secretase acting in the amyloid precursor 
protein cleavage process has never been confirmed. However, in 
three studies done, three members of the ADAM (A Disintegin 
And Metalloproteinase) family, ADAM9, ADAM10, and ADAM17, 
were suggested as possible a-secretases as their overexpression 
in cells or mice led to an increase in APP cleavage (Koike et al, 
1999; Lammich et al, 1999; Slack et al, 2001). To further pin-
point a single protease as the predominant a-secretase, knock-
out methods were used on the three ADAM metalloproteases. 
31
Is Detection of Preclinical Alzheimer’s Disease Possible?
Only ADAM 10 was found to completely suppress a-secretase 
cleavage of APP when knocked out. ADAM10, therefore, can be 
used as a measure of  a-secretase cleavage and its reduction can 
be used as a biomarker to detect preclinical Alzheimer’s disease 
(Kuhn et al., 2013).
In patients with Alzheimer’s disease, platelet levels of 
ADAM10 were reduced. A study was done to determine wheth-
er ADAM10 could act as an a-secretase and whether obtaining 
measurements of ADAM10 from platelets in blood plasma was 
an accurate measurement of ADAM10 levels in the brain. When 
compared to levels in cerebral spinal fluid, ADAM10 levels in 
platelets were similar. This was done because platelets present 
the highest levels of APP among the peripheral tissues (Colciaghi 
et al., 2002).
A study was done of two groups of Brazilian elderly peo-
ple to compare ADAM10 protein levels in participants with 
Alzheimer’s disease versus non-Alzheimer’s disease participants. 
By studying the platelet levels of ADAM10 as the only statis-
tically significant factor to increase probability of Alzheimer’s 
disease, it was found that ADAM10 levels were significantly 
reduced in patients with Alzheimer’s disease versus patients 
without it. The ADAM10 levels were also stage dependent; the 
further the disease had progressed, the lower the ADAM10 lev-
els were, indicating a decrease in a-secretase cleavage of APP 
(Manzine et. al., 2013). 
Conclusion
While many ethical concerns can be raised regarding the det-
rimental psychological effect of a preclinical Alzheimer’s disease 
diagnosis, most patients do not react with a negative emotion-
al response. On the contrary, an Alzheimer’s diagnosis often 
comes as a relief to patients and their families by delivering a 
cause for a patient’s cognitive decline (Carpenter et al., 2008).
Through the implementation of blood-based biomarkers, 
there is promise for easy detection of preclinical Alzheimer’s 
disease. A combination of testing levels of a-secretases like 
ADAM10 and specific cytokine and chemokine inflammatory 
markers can help lead to a definitive preclinical Alzheimer’s 
disease diagnosis. By using a combination of the above testing 
methods, Alzheimer’s disease will be able to be definitively diag-
nosed before symptoms appear, giving patients time to discuss 
therapies and make certain decisions on their own. However, 
these testing methods must still be regarded with caution as 
many of them have not been tested on a vast enough popula-
tion to be considered fool-proof. With further and more wide-
spread research on the above-mentioned biomarker possibili-
ties, there is promise for early and even preclinical detection of 
Alzheimer’s disease. Easy and early detection will not only help 
patients struggling with unknown causes of cognitive decline, 
but will lend to more reliable research for possible drugs to help 
cure this prevalent disease.
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